Review
doi: 10.1007/s40265-021-01644-5.
Atogepant: First Approval
Affiliations
- PMID: 34813050
- DOI: 10.1007/s40265-021-01644-5
Item in Clipboard
Review
Atogepant: First Approval
Drugs.
2022 Jan.
Abstract
Atogepant (Qulipta™) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine. In September 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults. The drug is also in phase 3 clinical development for the preventive treatment of migraine in various other countries. This article summarizes the milestones in the development of atogepant leading to this first approval for the preventive treatment of episodic migraine in adults.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Atogepant for the Preventive Treatment of Migraine.N Engl J Med. 2021 Aug 19;385(8):695-706. doi: 10.1056/NEJMoa2035908. N Engl J Med. 2021. PMID: 34407343 Clinical Trial.
-
Atogepant (Qulipta) for migraine prevention.Med Lett Drugs Ther. 2021 Nov 1;63(1636):169-171. Med Lett Drugs Ther. 2021. PMID: 35085204 No abstract available.
-
A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.Clin Pharmacol Drug Dev. 2021 Sep;10(9):1099-1107. doi: 10.1002/cpdd.940. Epub 2021 May 4. Clin Pharmacol Drug Dev. 2021. PMID: 33942560 Free PMC article. Clinical Trial.
-
Ubrogepant: First Approval.Drugs. 2020 Feb;80(3):323-328. doi: 10.1007/s40265-020-01264-5. Drugs. 2020. PMID: 32020557 Free PMC article. Review.
-
Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.Eur J Pharmacol. 2022 May 5;922:174902. doi: 10.1016/j.ejphar.2022.174902. Epub 2022 Mar 28. Eur J Pharmacol. 2022. PMID: 35358493 Review.
Cited by
-
Novel Macrocyclic Antagonists of the CGRP Receptor Part 2: Stereochemical Inversion Induces an Unprecedented Binding Mode.ACS Med Chem Lett. 2022 Oct 19;13(11):1776-1782. doi: 10.1021/acsmedchemlett.2c00400. eCollection 2022 Nov 10. ACS Med Chem Lett. 2022. PMID: 36385934 Free PMC article.
-
Research Progress in Calcitonin Gene-Related Peptide and Bone Repair.Biomolecules. 2023 May 15;13(5):838. doi: 10.3390/biom13050838. Biomolecules. 2023. PMID: 37238709 Free PMC article. Review.
-
Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine.Discoveries (Craiova). 2023 Jun 30;11(2):e167. doi: 10.15190/d.2023.6. eCollection 2023 Apr-Jun. Discoveries (Craiova). 2023. PMID: 37564925 Free PMC article. Review.
-
Unmet Needs in the Acute Treatment of Migraine.Adv Ther. 2024 Jan;41(1):1-13. doi: 10.1007/s12325-023-02650-7. Epub 2023 Nov 9. Adv Ther. 2024. PMID: 37943442 Free PMC article.
-
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.Naunyn Schmiedebergs Arch Pharmacol. 2022 Aug;395(8):867-885. doi: 10.1007/s00210-022-02250-2. Epub 2022 May 11. Naunyn Schmiedebergs Arch Pharmacol. 2022. PMID: 35543739 Free PMC article. Review.
References
-
- Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–14. - DOI
-
- de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020;211: 107528. https://doi.org/10.1016/j.pharmthera.2020.107528 . - DOI - PubMed
-
- Chan C, Goadsby PJ. Recent advances in pharmacotherapy for episodic migraine. CNS Drugs. 2019;33(11):1053–71. - DOI
-
- AbbVie. QULIPTA (atogepant) tablets, for oral use: US prescribing information. 2021. https://www.accessdata.fda.gov . Accessed 30 Sept 2021.
-
- AbbVie. FDA approves QULIPTA™ (atogepant), the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine [media release]. 28 Sept 2021. https://news.abbvie.com .
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
